Cancel anytime
GlycoMimetics Inc (GLYC)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/12/2024: GLYC (3-star) is a WEAK-BUY. BUY since 31 days. Profits (-45.65%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: WEAK BUY |
Historic Profit: 128.31% | Upturn Advisory Performance 3 | Avg. Invested days: 37 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 12/12/2024 |
Type: Stock | Today’s Advisory: WEAK BUY |
Historic Profit: 128.31% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 12/12/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.08M USD |
Price to earnings Ratio - | 1Y Target Price 1 |
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Volume (30-day avg) 2157127 | Beta 1.84 |
52 Weeks Range 0.14 - 3.53 | Updated Date 12/12/2024 |
Company Size Small-Cap Stock | Market Capitalization 18.08M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Dividends yield (FY) - | Basic EPS (TTM) -0.55 | Volume (30-day avg) 2157127 | Beta 1.84 |
52 Weeks Range 0.14 - 3.53 | Updated Date 12/12/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -408770.5% |
Management Effectiveness
Return on Assets (TTM) -59.25% | Return on Equity (TTM) -104.49% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 3951770 | Price to Sales(TTM) 1808.13 |
Enterprise Value to Revenue 395.18 | Enterprise Value to EBITDA -0.48 |
Shares Outstanding 64484000 | Shares Floating 42530394 |
Percent Insiders 3.12 | Percent Institutions 47.91 |
Trailing PE - | Forward PE - | Enterprise Value 3951770 | Price to Sales(TTM) 1808.13 |
Enterprise Value to Revenue 395.18 | Enterprise Value to EBITDA -0.48 | Shares Outstanding 64484000 | Shares Floating 42530394 |
Percent Insiders 3.12 | Percent Institutions 47.91 |
Analyst Ratings
Rating 5 | Target Price 5.5 | Buy - |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 5.5 | Buy - | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile: GlycoMimetics Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs. The company was founded in 2003 and is headquartered in Rockville, Maryland. GlycoMimetics specializes in the development of therapeutics for diseases involving inflammation, cell adhesion and cell trafficking. Their core business areas include drug development for acute and chronic diseases such as sickle cell disease, acute myeloid leukemia, and multiple myeloma.
The leadership team at GlycoMimetics is led by Dr. Rachel King, who serves as the CEO and President. Other key executives include John Magnani, Executive Vice President and Chief Operating Officer, and Brian Hahn, Senior Vice President and Chief Financial Officer. The company's corporate structure includes various departments such as research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share: GlycoMimetics' top product is rivipansel, a drug candidate being developed for the treatment of vaso-occlusive crisis in sickle cell disease. The market share of rivipansel in the global and US markets is still emerging as the drug is undergoing clinical trials. However, the potential for rivipansel to address the unmet medical needs of sickle cell disease patients is significant.
Total Addressable Market: The total addressable market for GlycoMimetics Inc. includes a broad range of acute and chronic diseases involving inflammation, cell adhesion, and cell trafficking. This market is estimated to be worth billions of dollars globally, with the potential for significant growth as new drug candidates are developed and brought to market.
Financial Performance: In the recent financial statements, GlycoMimetics Inc. reported revenue of $23.9 million, a net loss of $64.6 million, and an EPS of -$1.36. The company's profit margins are negative due to the heavy investment in research and development. The year-over-year financial performance shows an increase in revenue but also an increase in net loss. The cash flow statements indicate that the company has a steady cash position to support its ongoing operations. The balance sheet health shows that GlycoMimetics Inc. has a moderate level of debt compared to its assets.
Dividends and Shareholder Returns: GlycoMimetics Inc. does not pay dividends, as is common for early-stage biotechnology companies. Shareholder returns for the company have varied over time, depending on clinical trial outcomes, regulatory approval milestones, and market developments related to its drug candidates.
Growth Trajectory: Historically, GlycoMimetics Inc. has shown growth potential in its drug pipeline and research and development efforts. Future growth projections are positive based on industry trends and the company's guidance on advancing its drug candidates through clinical trials and potential commercialization. Recent product launches and strategic initiatives, such as partnerships with larger pharmaceutical companies, also support the growth trajectory of the company.
Market Dynamics: GlycoMimetics Inc. operates in the biotechnology industry, which is characterized by rapid technological advancements, high competition, and evolving regulatory landscapes. The company is positioned as a leader in glycomimetic drug development, with a strong focus on addressing unmet medical needs in areas such as sickle cell disease and acute myeloid leukemia. GlycoMimetics has shown adaptability to market changes by leveraging its scientific expertise and strategic collaborations.
Competitors: Key competitors of GlycoMimetics Inc. include companies such as Incyte Corporation (INCY) and Celgene Corporation. Glycomimetics' market share percentage may vary based on the successful development and commercialization of its drug candidates compared to these competitors. The company's competitive advantage lies in its unique approach to glycomimetic drug design and its focus on niche therapeutic areas.
Potential Challenges and Opportunities: Key challenges for GlycoMimetics Inc. include regulatory hurdles, clinical trial outcomes, and competitive pressures in the biotechnology industry. However, potential opportunities for the company include expanding into new markets, developing innovative drug candidates, and forming strategic partnerships to drive growth and value creation.
Recent Acquisitions (last 3 years): GlycoMimetics Inc. has not made any significant acquisitions in the last three years. The company's focus has been on advancing its internal pipeline of drug candidates through clinical development stages.
AI-Based Fundamental Rating: Based on an AI-based rating system, GlycoMimetics Inc. receives a rating of 7 out of 10. This rating is justified by the company's strong focus on innovative drug development, positive growth trajectory, and potential for market success. However, the negative profit margins and ongoing clinical trial risks are factors that may impact the overall rating.
Sources and Disclaimers: Sources used for this analysis include GlycoMimetics Inc.'s official website, financial reports, industry publications, and market research data. This overview is for informational purposes only and should not be considered as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlycoMimetics Inc
Exchange | NASDAQ | Headquaters | Rockville, MD, United States |
IPO Launch date | 2014-01-10 | CEO, President & Director | Mr. Harout Semerjian |
Sector | Healthcare | Website | https://www.glycomimetics.com |
Industry | Biotechnology | Full time employees | 35 |
Headquaters | Rockville, MD, United States | ||
CEO, President & Director | Mr. Harout Semerjian | ||
Website | https://www.glycomimetics.com | ||
Website | https://www.glycomimetics.com | ||
Full time employees | 35 |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.